What Foundayo is
Foundayo (generic name orforglipron) is a once-daily oral small-molecule GLP-1 receptor agonist made by Eli Lilly and Company.[1][2] In plain terms, it belongs to the same broad family of weight-management drugs as the GLP-1 injections the UK already knows — Mounjaro and Wegovy — but it works as a tablet, and it is chemically a different sort of molecule.
The US Food and Drug Administration approved Foundayo on 1 April 2026 for adults with obesity, or some adults who are overweight and also have weight-related medical problems, to reduce excess body weight and keep it off long term, alongside a reduced-calorie diet and more physical activity.[1] It was cleared under application number NDA 220934.[3] Lilly describes it as the only GLP-1 pill for weight loss that can be taken at any time of day, with or without food or water.[1]
Foundayo is a daily pill, not an injection, and it is a small-molecule (non-peptide) GLP-1 receptor agonist — the feature that lets it be taken any time, with or without food or water. It is approved in the US (April 2026) but has no MHRA licence, so there is no lawful way to obtain it in the UK today.
Why a GLP-1 pill is a genuinely big deal
There are two things that make orforglipron notable, and both come back to the same underlying fact: it is a small molecule, not a peptide.
No food or water rules
Peptide medicines are fragile in the stomach, which is why the existing oral GLP-1 option has come wrapped in strict timing rules — take it on an empty stomach, with only a little water, then wait before eating or drinking. Foundayo has none of that. Because it is a conventional small-molecule compound, it does not need those absorption-protecting restrictions, so it can be taken at any time of day, with or without food, and with or without water.[2][4] For a medicine meant to be taken every day for a long time, a simpler routine is not a trivial detail — it is the difference between a rule that is easy to keep and one that is easy to break. Our Wegovy pill page covers the more restrictive oral-semaglutide approach for comparison.
Manufacturing at scale
The second consequence is about supply. A small molecule can be synthesised chemically and scaled up at far greater volume than an injectable peptide, which is the basis of Lilly's strategy to supply an oral GLP-1 at mass-market scale.[2] That does not change anything for a UK patient today — you still cannot lawfully get it here — but it is why a pill version of this drug class has attracted so much attention: if it can be made in the quantities its makers hope, it could eventually be available far more widely than the injections, which have been dogged by shortages.
What the ATTAIN-1 trial found
The headline efficacy data come from ATTAIN-1, a phase 3, 72-week, randomised, double-blind, placebo-controlled trial of 3,127 adults who had obesity (or were overweight with weight-related conditions) but who did not have type 2 diabetes, run across 10 countries. The trial tested three research doses — 6mg, 12mg and 36mg — against placebo, on top of diet and physical activity.[2]
| Group | Average weight change | Reached ≥10% loss | Reached ≥15% loss |
|---|---|---|---|
| 6mg | −7.8% | 35.9% | 16.5% |
| 12mg | −9.3% | 45.1% | 24.0% |
| 36mg | −12.4% | 59.6% | 39.6% |
| Placebo | −0.9% | 8.6% | 3.6% |
The pattern is dose-dependent: more of the medicine, more weight lost, but also more side effects (see below). On the highest 36mg dose, average weight change was about −12.4%, against about −0.9% on placebo.[2] These are trial averages achieved alongside diet and exercise; an individual's result can be higher or lower. A companion trial, ATTAIN-2, tested orforglipron in people who also had type 2 diabetes and was reported by Lilly as a successful third phase 3 study, showing weight loss and blood-sugar (A1C) improvements in that group.[6]
Side effects seen in the trial
As with the whole GLP-1 class, the most common side effects were gastrointestinal, mostly mild to moderate, and more frequent at higher doses.[2] In ATTAIN-1:
- Nausea affected roughly 28.9% to 35.9% of people on orforglipron across the dose groups, against 10.4% on placebo.[2]
- Constipation ranged from about 21.7% to 29.8%, versus 9.3% on placebo.[2]
- Diarrhoea ranged from about 21.0% to 23.1%, versus 9.6% on placebo.[2]
- Vomiting ranged from about 13.0% to 24.0%, versus 3.5% on placebo.[2]
- Stopping the medicine because of side effects rose with dose, from 5.3% to 10.3%, against 2.7% on placebo.[2]
The US label also carries a boxed warning about thyroid C-cell tumours, including medullary thyroid carcinoma, and lists a personal or family history of medullary thyroid carcinoma, and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as contraindications.[3][9] This page summarises rather than reproduces the label; the full, authoritative warnings live in the official prescribing information.
If you ever take a weight-loss medicine and have a side effect, you can report it to the UK regulator through the MHRA Yellow Card scheme[8] and speak to your GP or pharmacist. Reporting helps the MHRA monitor the safety of medicines.
How Foundayo is taken
Foundayo is a once-daily tablet made in six strengths — 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg and 17.2mg — and the dose is built up gradually. Treatment starts at 0.8mg once daily, with each step held for at least about 30 days before any increase, up to a maximum of 17.2mg once daily; the maintenance range is 5.5mg to 17.2mg, and the prescriber chooses the dose based on how well someone responds and tolerates it.[4][5] The slow climb exists to reduce the risk of the gastrointestinal side effects above.[5] This is the US dosing; there is no UK dosing yet because there is no UK licence.
Where approval stands: US yes, UK not yet
Foundayo is approved and available in the United States. In the UK it is not approved. As of mid-2026, Lilly has said it submitted orforglipron to regulators in dozens of countries, including the UK, but the MHRA has not licensed it, and neither Lilly nor the MHRA has confirmed a decision date. Industry commentators have suggested a UK decision might come somewhere around late 2026 to early 2027 — but that is an expectation, not a commitment, and even a licence would be only the first gate. NHS availability would then need a separate NICE appraisal of clinical and cost-effectiveness, as happened with Mounjaro and Wegovy, so any NHS route would realistically be later still and likely limited to defined patient groups. Our GLP-1 medication comparison sets Foundayo against the options already available here.
Because Foundayo has no MHRA licence, no lawful UK supply exists. Any website or seller offering "Foundayo" or "orforglipron" to UK customers today is acting illegally, and whatever they send is not a regulated medicine — it may be fake, contaminated or dangerous. You can learn how to spot illegal sellers of medicines through the MHRA's #FakeMeds campaign.[7] Please do not buy it from anyone claiming to supply it in the UK.
How Foundayo fits with the other GLP-1 medicines
Foundayo is one member of a growing group. The GLP-1 medicines a UK reader is most likely to have heard of are weekly injections — Mounjaro (tirzepatide) and Wegovy (semaglutide) — while the oral options are newer. Foundayo is a daily tablet and a distinct molecule from those. If you want the wider picture, our Mounjaro page and GLP-1 medication FAQ cover how these medicines differ and the questions people ask most. For a page dedicated entirely to this one drug, there is also a separate independent site, Foundayo Tablet UK, that tracks orforglipron in depth.
Frequently asked questions
What is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily GLP-1 pill from Eli Lilly. It is an oral small-molecule (non-peptide) GLP-1 receptor agonist, which is what allows it to be taken at any time of day with or without food or water. The US FDA approved it on 1 April 2026 for adults with obesity, or some adults with overweight who also have weight-related medical problems.
Is Foundayo a tablet instead of an injection?
Yes. It is an oral tablet taken once a day — no injection, no needle and no self-injection technique to learn. Lilly markets it as the only GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions.
How much weight did people lose on Foundayo in the trials?
In the 72-week ATTAIN-1 trial of 3,127 adults with obesity but without type 2 diabetes, average weight change on the highest 36mg research dose was about −12.4%, compared with about −0.9% on placebo. Results were smaller at lower doses. These are trial averages achieved alongside diet and exercise, and individual results vary.
Can I get Foundayo in the UK?
Not yet. It has no MHRA licence, so there is no lawful UK supply and it cannot be prescribed or sold here. Anyone offering to sell it to UK customers today is acting illegally, and what they supply is not a regulated medicine. Commentators expect an MHRA decision around late 2026 to early 2027, but no date is confirmed.
Is Foundayo the same as Mounjaro or Wegovy?
No. Mounjaro (tirzepatide) and Wegovy (semaglutide) are weekly injections; Foundayo (orforglipron) is a daily tablet and a different molecule. All sit within the broader GLP-1 family, but they differ in how they are taken, their dosing and their UK licensing status.
References
- Eli Lilly and Company. "FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss." Investor news release, April 2026. investor.lilly.com
- New England Journal of Medicine. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Adults with Obesity" (ATTAIN-1). nejm.org
- US Food and Drug Administration. Approval letter, NDA 220934 (Foundayo / orforglipron), 2026. accessdata.fda.gov
- Eli Lilly and Company. "How to take Foundayo." foundayo.lilly.com/how-to-take
- Eli Lilly and Company. "Foundayo dosage information for healthcare professionals." foundayo.lilly.com/hcp/dosage
- Eli Lilly and Company. "Lilly's oral GLP-1 orforglipron successful in third phase 3 trial" (ATTAIN-2). Investor news release. investor.lilly.com
- MHRA. "#FakeMeds — buying medicines safely online." fakemeds.campaign.gov.uk
- MHRA. "Yellow Card scheme — report a side effect." yellowcard.mhra.gov.uk
- Eli Lilly and Company / PR Newswire. "FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day, without food or water restrictions." News release, April 2026. prnewswire.com